Cargando…

Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis

BACKGROUND: The application of vedolizumab (VDZ) subcutaneous (SC) formulation has brought more convenience and hope to patients with moderate-to-severe inflammatory bowel diseases (IBDs) in the coronavirus disease 2019 context. OBJECTIVE: This study aimed to systematically evaluate all previous stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Qiong, Tang, Xing-zhou, Liu, Fang, Liu, De-wu, Cao, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141260/ https://www.ncbi.nlm.nih.gov/pubmed/37124368 http://dx.doi.org/10.1177/17562848231166227

Ejemplares similares

Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
por: Fenu, Elisabetta, et al.
Publicado: (2022)

Fr494 THE IMPACT OF VEDOLIZUMAB THERAPY ON COVID-19 OUTCOMES IN ADULT IBD PATIENTS IN THE SECURE-IBD REGISTRY
por: Agrawal, Manasi, et al.
Publicado: (2021)

Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy
por: Abreu, Maria T, et al.
Publicado: (2022)

The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2021)

Deciphering the vedolizumab dosing conundrum in IBD: when less is more
por: Adolph, Timon Erik, et al.
Publicado: (2022)

Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD
por: Soendergaard, Christoffer, et al.
Publicado: (2018)

Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis
por: Moćko, Paweł, et al.
Publicado: (2016)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
por: Kobayashi, Taku, et al.
Publicado: (2021)

Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience
por: Remy, Clotilde, et al.
Publicado: (2022)

Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
por: Mühl, Laura, et al.
Publicado: (2021)

Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients
por: Breidert, Matthias, et al.
Publicado: (2020)

Vedolizumab for induction and maintenance of remission in Crohn's disease
por: Hui, Samuel, et al.
Publicado: (2023)

Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort
por: Bamias, Giorgos, et al.
Publicado: (2021)

Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Pagkali, Antonia, et al.
Publicado: (2022)

Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis
por: Jena, Anuraag, et al.
Publicado: (2022)

Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
por: Naganuma, Makoto, et al.
Publicado: (2021)

ESPNIC clinical practice guidelines: intravenous maintenance fluid therapy in acute and critically ill children— a systematic review and meta-analysis
por: Brossier, David W., et al.
Publicado: (2022)

Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations
por: Burdge, Gemma, et al.
Publicado: (2022)

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay
por: Vande Casteele, Niels, et al.
Publicado: (2023)

Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis
por: Ayoub, Fares, et al.
Publicado: (2022)

Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study
por: Pugliese, Daniela, et al.
Publicado: (2022)

Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
por: Alexander, James L., et al.
Publicado: (2022)

A Systematic Review and Meta-Analysis of Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections in Type-2 Diabetes
por: Chatziravdeli, Vasiliki, et al.
Publicado: (2023)

Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience
por: Oršić Frič, Vlasta, et al.
Publicado: (2023)

Efficacy and Safety of Subcutaneous Allergen-Specific Immuno-Therapy in Horses with Allergic Cutaneous and Respiratory Diseases—A Systematic Review
por: Herrmann, Ina, et al.
Publicado: (2023)

Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis
por: Schultz, Bob G, et al.
Publicado: (2021)

Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Auricular Acupressure for Dry Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Huang, Qiong, et al.
Publicado: (2023)

Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective
por: Jonaitis, Laimas, et al.
Publicado: (2021)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

Vedolizumab Therapy in Refractory Enteropathy Associated With CVID
por: Johnson, Dane, et al.
Publicado: (2021)

The Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Infection: A Systematic Review and Network Meta-Analysis
por: Liu, Ligang, et al.
Publicado: (2023)

Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
por: Bergqvist, Viktoria, et al.
Publicado: (2022)

The prevalence of osteoporotic fractures in the elderly in China: a systematic review and meta-analysis
por: Meng, Shilong, et al.
Publicado: (2023)

Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Systematic Review and Meta‐Analysis of Randomized Trials and Propensity Score–Matched Studies
por: Fong, Khi Yung, et al.
Publicado: (2022)

Subcutaneous Emphysema as a Complication of Tonsillectomy: A Systematic Literature Review and Case Report
por: Saravakos, Panagiotis, et al.
Publicado: (2018)

Polypharmacy as maintenance treatment in bipolar illness: A systematic review
por: Amerio, Andrea, et al.
Publicado: (2021)

Improving health maintenance supervision in a paediatric IBD clinic
por: Dykes, Dana M H, et al.
Publicado: (2017)

Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis
por: Liu, Min-Hui, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_s63tekesjlv1nqicmnfkf6g1d6